ANAkinra for the treatment of CORonavirus infectious disease 2019 at the Intensive Care (ANACOR-IC)

ANACOR-IC focusses on critically ill COVID-19 patients treated with anakinra as part of their treatment regimen. Anakinra is an IL-1 blocker, central to the detrimental immune response that occurs in severely ill patients with COVID-19. For this study, patients randomized within the COVID-19 Immune Modulation domain of REMAP-CAP (to anakinra, no intervention, or other immune modulators) will be sampled, and immune profile, coagulation and -omics data will be combined with clinical data to produce a unique dataset. REMAP-CAP is an international Adaptive Platform Trial that investigates the best treatment for hospitalized patients with COVID-19. It was set up to include severely ill CAP patients and to adapt in case of a pandemic, as has now occurred in the SARS-CoV-2 pandemic. ANACOR-IC aims to provide detailed insight into the pathophysiological mechanisms and effectiveness of anakinra for this novel disease.